Intellectual Property & Technology Commercialization Program:
Investing in Innovation

The Intellectual Property & Technology Commercialization Program embodies the spirit of the National Jewish Health brand promise, Science Transforming Life®. We accelerate the development of basic scientific research towards clinical application by identifying and protecting the Center's intellectual property and facilitating business partnerships for technology development, licensing, and commercialization. National Jewish Health has close to 150 technologies in its active portfolio and owns 55 active issued U.S. patents  plus additional corresponding foreign patents.  We have executed 155 license agreements—of which 92 are still active—and helped create 8 start-up companies.

To browse a list of the technologies ready for licensing or further development, select one of the following:

• Biotechnologies: By type and application or by title
  
• Research Tools:  Antibodies,  Animal models & Transgenic Mice
  
• Biomedical devices
  
• FEATURED TECHNOLOGY:  Novel Phospholipid-Based TLR Inhibitors
  

   

Transforming Our Discoveries into Therapeutics
	Akela Pharma is currently conducting Phase IIb trials of a National Jewish Health developed technology, CGRP. CGRP is a 37 amino acid natural neuropeptide produced in the lung in response to allergic stimuli. As a potential drug, it has demonstrated in preclinical studies a profile that could make it an ideal anti-asthmatic drug candidate with bronchodilator, bronchoprotector and anti-inflammatory properties.
	Aeolus Pharmaceuticals is developing AEOL 10150, a small molecule catalytic antioxidant that has shown the ability to scavenge a broad range of reactive oxygen species.  AEOL 10150 is currently undergoing human clinical evaluation in patients with ALS.  James Crapo, MD, and Brian Day, PhD, of National Jewish Health are inventors on the intellectual property underlying this discovery.
	Juvaris BioTherapeutics was founded in 2003, based on the intellectual property developed at National Jewish Health by Steven Dow, DVM, PhD. Juvaris BioTherapeutics is developing therapeutic vaccines for cancer and infectious diseases using its novel technology platform of cationic lipids and non-coding DNA complexes.
	Innate Pharma  licensed intellectual property developed by Willi Born, PhD, and Erwin Gelfand, MD, relating to the use of compounds stimulating gamma delta T cells in the treatment of certain respiratory diseases. These compounds are currently in preclinical testing. Innate Pharma SA is a French biopharmaceutical company developing first-in-class drugs targeting the innate immune system.
	Taiga Biotechnologies was founded to develop novel approaches to treat hematological diseases, including cancers, immunodeficiencies and autoimmune conditions. Their three-pronged approach combines novel breakthroughs by Yosef Refaeli, PhD, John Cambier, PhD, and colleagues at National Jewish Health and University of Colorado Denver in cellular, biologic and small molecule approaches to treat and manage these diseases.
	Taligen Therapeutics, Inc ., which was founded in March 2004 by Drs. Woody Emlen and V. Michael Holers, is working to develop and commercialize technologies created by scientists from National Jewish Health (Erwin Gelfand, MD) and the University of Colorado. Taligen is a development stage biotechnology company focused on the treatment of serious inflammatory diseases including asthma, macular degeneration and immune kidney disease. The Company employs novel technologies designed to modulate and regulate activation of the complement system.
	VistaGen applies their innovative in vitro embryonic stem (ES) cell technologies to discover and develop new generation drugs and protein biologics, both internally and through strategic collaborations with the pharmaceutical and biotechnology industries. Vistagen’s clinically predictive in vitro embryonic stem cell technologies are based on intellectual property developed at National Jewish by Gordon Keller, PhD.

Additional Services

The Intellectual Property and Technology Commercialization Program is also responsible for:

• Licensing non-patented biological materials developed in National Jewish Health laboratories
• Review, negotiation, and approval of Materials Transfer Agreements
• Approval for use of National Jewish Health copyrighted materials
  • Copyright Permission Request Form
• Management and licensing, where appropriate, of National Jewish Health trademarks and copyrights

Staff

Our Address:
National Jewish Health
Intellectual Property and Technology Commercialization
1400 Jackson St., M206
Denver, CO 80206
Facsimile: 303-270-2352